Greenwich LifeSciences The Overlooked Need

Greenwich LifeSciences is a single-asset biotech focused on GLSI-100, an immunotherapy for HER2-positive breast cancer, currently in Phase 3 trials. GLSI-100 demonstrated a 70-80% reduction in cancer recurrence in Phase 2b, outperforming approved therapies, with no serious adverse events reported. GLSI trades at a ~$279M market cap, below recent M&A comps, despite advanced clinical progress and a large addressable market in HER2/neu-positive breast cancer. Risks include binary dependency on GLSI-100 Phase 3 success and near-term need for additional capital, given limited cash reserves. The Thesis: Greenwich LifeSciences ( GLSI ) is a single-asset small-cap biotechnology company. The current market capitalization of Greenwich supports my belief that the market is overlooking their favorable safety and efficacy profiles, as well as the This article was written by Max Arnoldi 33 Followers Follow Max is an independent equity research analyst with a primary focus on biotechnology, healthcare, and technology companies. His investment approach is fundamentally driven, combining detailed financial modeling, valuation analysis, and in-depth research into clinical trial data, regulatory pathways, competitive dynamics, commercialization potential, and long-term business fundamentals. He is currently pursuing his academic studies while continuing to expand his expertise in equity research and financial analysis. He has gained additional experience through work exposure at the Deutsche Bundesbank and EY, where he developed a deeper understanding of financial systems and professional analysis standards. Through Seeking Alpha, Max aims to publish independent, research-driven analysis of biotechnology and healthcare companies, translating clinical and financial data into actionable investment insights. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in GLSI over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.